Association between clinical laboratory indicators and WOMAC scores in Qatar Biobank participants: The impact of testosterone and fibrinogen on pain, stiffness, and functional limitation.
Ovelia Masoud, Linzette Morris, Mohammed Al-Hamdani, Amal Al-Haidose, Atiyeh M Abdallah
{"title":"Association between clinical laboratory indicators and WOMAC scores in Qatar Biobank participants: The impact of testosterone and fibrinogen on pain, stiffness, and functional limitation.","authors":"Ovelia Masoud, Linzette Morris, Mohammed Al-Hamdani, Amal Al-Haidose, Atiyeh M Abdallah","doi":"10.1515/sjpain-2024-0045","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The association between baseline laboratory parameters and experienced well-being in healthy individuals remains uncertain. This study explored the relationship between clinical laboratory profiles and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores for pain, stiffness, and physical functional limitation in healthy individuals in Qatar.</p><p><strong>Methods: </strong>Clinical laboratory data were collected from 1,764 Qatar Biobank participants who also completed the WOMAC questionnaire: lipid profiles (high-density lipoprotein, low-density lipoprotein, cholesterol, and triglycerides), endocrine markers (TSH, T3, T4, estradiol, and testosterone), and two inflammatory markers (CRP and fibrinogen). Multiple linear regression was used with 11 clinical indicators as independent variables and the subscale and total WOMAC scores as dependent variables. Multivariate effects of each indicator on the outcomes were assessed, and univariate effects were examined when significant.</p><p><strong>Results: </strong>Testosterone had a significant impact on all WOMAC subscales (pain, stiffness, and functional limitation) and the total WOMAC score. Higher testosterone levels were associated with a reduction in pain (<i>β</i> = -0.03, <i>t</i> = -3.505, <i>p</i> < 0.001, 95% CI = -0.052, -0.015), stiffness (<i>β</i> = -0.01, <i>t</i> = -2.265, <i>p</i> = 0.024, 95% CI = -0.018, -0.001), physical dysfunction (<i>β</i> = -0.08, <i>t</i> = -3.265, <i>p</i> = 0.001, 95% CI = -0.135, -0.034), and total WOMAC scores (<i>β</i> = -0.127, <i>t</i> = -3.444, <i>p</i> < 0.001, 95% CI = -0.199, -0.055). Elevated fibrinogen levels were associated with an increase in stiffness (<i>β</i> = 0.155, <i>t</i> = 2.241, <i>p</i> = 0.025, 95% CI = 0.019, 0.290), physical dysfunction (<i>β</i> = 1.17, <i>t</i> = 2.808, <i>p</i> = 0.005, 95% CI = 0.354, 1.997), and total WOMAC scores (<i>β</i> = 1.610, <i>t</i> = 2.691, <i>p</i> = 0.007, 95% CI = 0.437, 2.784).</p><p><strong>Conclusion: </strong>Testosterone may protect against pain, stiffness, and physical dysfunction, while high fibrinogen levels might be a surrogate of systemic inflammation that enhances stiffness and limits physical function. Measuring multiple clinical and laboratory markers in healthy individuals may enhance our understanding of the molecular mechanisms underlying pain.</p>","PeriodicalId":47407,"journal":{"name":"Scandinavian Journal of Pain","volume":"25 1","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Pain","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/sjpain-2024-0045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: The association between baseline laboratory parameters and experienced well-being in healthy individuals remains uncertain. This study explored the relationship between clinical laboratory profiles and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores for pain, stiffness, and physical functional limitation in healthy individuals in Qatar.
Methods: Clinical laboratory data were collected from 1,764 Qatar Biobank participants who also completed the WOMAC questionnaire: lipid profiles (high-density lipoprotein, low-density lipoprotein, cholesterol, and triglycerides), endocrine markers (TSH, T3, T4, estradiol, and testosterone), and two inflammatory markers (CRP and fibrinogen). Multiple linear regression was used with 11 clinical indicators as independent variables and the subscale and total WOMAC scores as dependent variables. Multivariate effects of each indicator on the outcomes were assessed, and univariate effects were examined when significant.
Results: Testosterone had a significant impact on all WOMAC subscales (pain, stiffness, and functional limitation) and the total WOMAC score. Higher testosterone levels were associated with a reduction in pain (β = -0.03, t = -3.505, p < 0.001, 95% CI = -0.052, -0.015), stiffness (β = -0.01, t = -2.265, p = 0.024, 95% CI = -0.018, -0.001), physical dysfunction (β = -0.08, t = -3.265, p = 0.001, 95% CI = -0.135, -0.034), and total WOMAC scores (β = -0.127, t = -3.444, p < 0.001, 95% CI = -0.199, -0.055). Elevated fibrinogen levels were associated with an increase in stiffness (β = 0.155, t = 2.241, p = 0.025, 95% CI = 0.019, 0.290), physical dysfunction (β = 1.17, t = 2.808, p = 0.005, 95% CI = 0.354, 1.997), and total WOMAC scores (β = 1.610, t = 2.691, p = 0.007, 95% CI = 0.437, 2.784).
Conclusion: Testosterone may protect against pain, stiffness, and physical dysfunction, while high fibrinogen levels might be a surrogate of systemic inflammation that enhances stiffness and limits physical function. Measuring multiple clinical and laboratory markers in healthy individuals may enhance our understanding of the molecular mechanisms underlying pain.
目的:基线实验室参数与健康个体体验幸福感之间的关系仍不确定。本研究探讨了临床实验室资料与西安大略省和麦克马斯特大学在卡塔尔健康个体中疼痛、僵硬和身体功能限制的骨关节炎指数(WOMAC)评分之间的关系。方法:收集1764名卡塔尔生物银行参与者的临床实验室数据,这些参与者还完成了WOMAC问卷调查:脂质谱(高密度脂蛋白、低密度脂蛋白、胆固醇和甘油三酯)、内分泌标志物(TSH、T3、T4、雌二醇和睾酮)和两种炎症标志物(CRP和纤维蛋白原)。采用多元线性回归,以11项临床指标为自变量,WOMAC亚量表和总分为因变量。评估每个指标对结果的多变量影响,并在显著时检查单变量影响。结果:睾酮对所有WOMAC亚量表(疼痛、僵硬和功能限制)和WOMAC总分有显著影响。较高的睾酮水平与疼痛(β = -0.03, t = -3.505, p < 0.001, 95% CI = -0.052, -0.015)、僵硬(β = -0.01, t = -2.265, p = 0.024, 95% CI = -0.018, -0.001)、身体功能障碍(β = -0.08, t = -3.265, p = 0.001, 95% CI = -0.135, -0.034)和WOMAC总分(β = -0.127, t = -3.444, p < 0.001, 95% CI = -0.199, -0.055)的减轻有关。纤维蛋白原水平升高与僵硬度增加(β = 0.155, t = 2.241, p = 0.025, 95% CI = 0.019, 0.290)、身体功能障碍(β = 1.17, t = 2.808, p = 0.005, 95% CI = 0.354, 1.997)和WOMAC总评分(β = 1.610, t = 2.691, p = 0.007, 95% CI = 0.437, 2.784)相关。结论:睾酮可以预防疼痛、僵硬和身体功能障碍,而高纤维蛋白原水平可能是全身性炎症的替代品,可增强僵硬和限制身体功能。在健康个体中测量多种临床和实验室标记物可以增强我们对疼痛的分子机制的理解。